These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16831997)

  • 1. Predicting cardiovascular risk: so what do we do now?
    Lloyd-Jones DM; Tian L
    Arch Intern Med; 2006 Jul; 166(13):1342-4. PubMed ID: 16831997
    [No Abstract]   [Full Text] [Related]  

  • 2. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
    Folsom AR; Chambless LE; Ballantyne CM; Coresh J; Heiss G; Wu KK; Boerwinkle E; Mosley TH; Sorlie P; Diao G; Sharrett AR
    Arch Intern Med; 2006 Jul; 166(13):1368-73. PubMed ID: 16832001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two markers complement each other in identifying risk.
    SoRelle R
    Circulation; 2004 Feb; 109(7):e9012. PubMed ID: 14981022
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
    Greenland P; O'Malley PG
    Arch Intern Med; 2005 Nov; 165(21):2454-6. PubMed ID: 16314539
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
    Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
    N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?].
    Piñón P; Kaski JC
    Rev Esp Cardiol; 2006 Mar; 59(3):247-58. PubMed ID: 16712749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory markers of coronary risk.
    Rader DJ
    N Engl J Med; 2000 Oct; 343(16):1179-82. PubMed ID: 11036126
    [No Abstract]   [Full Text] [Related]  

  • 10. New test predicts heart risk.
    FDA Consum; 2003; 37(5):6. PubMed ID: 14666894
    [No Abstract]   [Full Text] [Related]  

  • 11. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
    ; Kaptoge S; Di Angelantonio E; Lowe G; Pepys MB; Thompson SG; Collins R; Danesh J
    Lancet; 2010 Jan; 375(9709):132-40. PubMed ID: 20031199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for prediction of cardiovascular events.
    Ridker PM; Cook NR
    N Engl J Med; 2007 Apr; 356(14):1472-3; author reply 1474-5. PubMed ID: 17415901
    [No Abstract]   [Full Text] [Related]  

  • 13. C-reactive protein and coronary heart disease.
    Glynn RJ; Cook NR
    N Engl J Med; 2004 Jul; 351(3):295-8; author reply 295-8. PubMed ID: 15254289
    [No Abstract]   [Full Text] [Related]  

  • 14. New tests for heart disease: promise but no payoff. Three new blood tests designed to detect early heart disease aren't quite ready for prime time.
    Harv Heart Lett; 2005 Jul; 15(11):6--7. PubMed ID: 16149177
    [No Abstract]   [Full Text] [Related]  

  • 15. Coronary disease risk prediction algorithm warranting incorporation of C-reactive protein in Turkish adults, manifesting sex difference.
    Onat A; Can G; Hergenç G; Uğur M; Yüksel H
    Nutr Metab Cardiovasc Dis; 2012 Aug; 22(8):643-50. PubMed ID: 21315565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
    Honda H; Qureshi AR; Heimbürger O; Barany P; Wang K; Pecoits-Filho R; Stenvinkel P; Lindholm B
    Am J Kidney Dis; 2006 Jan; 47(1):139-48. PubMed ID: 16377395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults.
    Onat A; Can G; Çiçek G; Ayhan E; Doğan Y; Kaya H
    Acta Diabetol; 2013 Aug; 50(4):519-28. PubMed ID: 21769500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Inflammatory Markers and the Risk of Developing Hypertension in Men.
    Sesso HD; Jiménez MC; Wang L; Ridker PM; Buring JE; Gaziano JM
    J Am Heart Assoc; 2015 Sep; 4(9):e001802. PubMed ID: 26391130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
    Oei HH; van der Meer IM; Hofman A; Koudstaal PJ; Stijnen T; Breteler MM; Witteman JC
    Circulation; 2005 Feb; 111(5):570-5. PubMed ID: 15699277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions.
    Iribarren C
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):5-6. PubMed ID: 16373620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.